Metabolite profiling in retinoblastoma identifies novel clinicopathological subgroups by Kohe, Sarah et al.
 
 
University of Birmingham
Metabolite profiling in retinoblastoma identifies
novel clinicopathological subgroups
Kohe, Sarah; Brundler, Marie-Anne ; Jenkinson, Helen; Parulekar, Manoj; Wilson, Martin;
Peet, Andrew C; McConville, Carmel M
DOI:
10.1038/bjc.2015.318
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Kohe, S, Brundler, M-A, Jenkinson, H, Parulekar, M, Wilson, M, Peet, AC & McConville, CM 2015, 'Metabolite
profiling in retinoblastoma identifies novel clinicopathological subgroups', British Journal of Cancer, vol. 113, no.
8, pp. 1216–1224. https://doi.org/10.1038/bjc.2015.318
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository : checked 16/10/2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Metabolite profiling in retinoblastoma
identifies novel clinicopathological subgroups
Sarah Kohe1, Marie-Anne Brundler2,5, Helen Jenkinson3, Manoj Parulekar4, Martin Wilson1, Andrew C Peet1,3,6
and Carmel M McConville*,1,6 on behalf of the Children’s Cancer and Leukaemia Group (CCLG)
1School of Cancer Sciences, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK; 2Department of Histopathology,
Birmingham Children’s Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK; 3Department of Oncology, Birmingham Children’s
Hospital, Steelhouse Lane, Birmingham B4 6NH, UK and 4Department of Ophthalmology, Birmingham Children’s Hospital,
Steelhouse Lane, Birmingham B4 6NH, UK
Background: Tumour classification, based on histopathology or molecular pathology, is of value to predict tumour behaviour and
to select appropriate treatment. In retinoblastoma, pathology information is not available at diagnosis and only exists for
enucleated tumours. Alternative methods of tumour classification, using noninvasive techniques such as magnetic resonance
spectroscopy, are urgently required to guide treatment decisions at the time of diagnosis.
Methods: High-resolution magic-angle spinning magnetic resonance spectroscopy (HR-MAS MRS) was undertaken on enucleated
retinoblastomas. Principal component analysis and cluster analysis of the HR-MAS MRS data was used to identify tumour
subgroups. Individual metabolite concentrations were determined and were correlated with histopathological risk factors for each
group.
Results: Multivariate analysis identified three metabolic subgroups of retinoblastoma, with the most discriminatory metabolites
being taurine, hypotaurine, total-choline and creatine. Metabolite concentrations correlated with specific histopathological
features: taurine was correlated with differentiation, total-choline and phosphocholine with retrolaminar optic nerve invasion, and
total lipids with necrosis.
Conclusions: We have demonstrated that a metabolite-based classification of retinoblastoma can be obtained using ex vivo
magnetic resonance spectroscopy, and that the subgroups identified correlate with histopathological features. This result justifies
future studies to validate the clinical relevance of these subgroups and highlights the potential of in vivo MRS as a noninvasive
diagnostic tool for retinoblastoma patient stratification.
An estimated 5000–8000 new cases of retinoblastoma are diagnosed
worldwide each year (40–50 in the United Kingdom), representing
4% of all childhood cancers (Abramson, 2005). Enucleation of the
affected globe has long been considered the most effective treatment
and is associated with survival rates approaching 100% in developed
countries. Over recent years, there has been an increasing emphasis,
however, on more conservative treatments to minimise loss of
vision, problems associated with prosthesis fitting and maintenance,
as well as the emotional and behavioural adjustments required in
patients (van Dijk et al, 2007). This is particularly important for
patients with heritable retinoblastoma (B40% of the total) who have
a high risk of bilateral disease.
Conservative treatments such as cryotherapy and laser therapy,
in some cases combined with systemic chemotherapy, are now well
established for retinoblastomas classified as low grade (grades A–C
according to the International Intraocular Classification of
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Retinoblastoma) (Sastre et al, 2009). However, primary enucleation
is more frequently the treatment of choice for high-grade tumours
(grades D and E) as B25% of these will show adverse
histopathological features following enucleation, for example,
retrolaminar invasion of the optic nerve, massive choroidal
invasion or involvement of the anterior chamber (Yousef et al,
2014). These features are considered to present a significant
risk for extraocular metastasis (Shields and Shields, 2004) and
thus patients also receive additional systemic chemotherapy
post-enucleation. Delayed diagnosis and suboptimal therapy
are associated with mortality rates of up to 70% in some
developing countries as a consequence of tumour metastasis
(Kivela, 2009).
More recently, the development of more effective methods for
administration of chemotherapy using targeted intra-arterial or
intra-vitreal approaches means that these are now being used
increasingly as alternatives to enucleation. These methods have
proved to be highly effective in the treatment of high-grade
retinoblastoma, allowing globe salvage in 60–70% of cases (Munier
et al, 2013; Shields et al, 2014). Nevertheless, a consequence of this
development is that fewer globes undergo histopathological
examination for high-risk features, which would otherwise prompt
treatment with systemic chemotherapy to eliminate possible
micrometastatic spread. Thus, it is possible that a cohort of children,
who would have received chemotherapy for high-risk features if
enucleated, will be significantly undertreated with intra-arterial/-
vitreal chemotherapy and will face a greater risk of subsequent
metastatic relapse. It has been reported, for example, that two
patients in a series of 78 (2.5%) developed metastatic disease after
intra-arterial chemotherapy (Gobin et al, 2011). At present, there are
no reliable noninvasive methods to identify high-risk pathology
before treatment (biopsy is contraindicated as it presents a risk of
extraocular spread). There is an urgent need therefore to develop
noninvasive tumour markers that could differentiate between
retinoblastomas which could be treated conservatively, and those
for which enucleation is still the safest option.
A potential solution to this problem is provided by the use of
magnetic resonance spectroscopy (MRS), for the detection of
tumour metabolites that may serve as biomarkers for tumour
stratification. Ex vivo studies using high-resolution magic-angle
spinning magnetic resonance spectroscopy (HR-MAS MRS) of
resected tumour tissue have shown the utility of this method for
tumour diagnosis and subtyping in brain, lung, pancreatic, gastric
and colon cancers (Wilson et al, 2009a; Jung et al, 2014; Mirnezami
et al, 2014; Rocha et al, 2014; Wang et al, 2014). Tumour
metabolites have also been shown to correlate with tumour-specific
genetic mutations, for example, IDH1 mutation in glioma, SDH
and VHL mutations in paraganglioma and MYCN amplification in
neuroblastoma (Peet et al, 2007; Imperiale et al, 2013; Esmaeili
et al, 2014). Furthermore, and of particular relevance to
retinoblastoma, is the demonstration that clinically important
information may also be obtained noninvasively using in vivo
MRS. This approach has been used to distinguish between different
types of brain tumours and to predict survival of patients with
these tumours (Orphanidou-Vlachou et al, 2013; Vicente et al,
2013; Wilson et al, 2013). In vivo MRS has also been used
successfully to provide diagnostic and prognostic information
about prostate, breast and pancreatic cancers (Yao et al, 2012;
Selnaes et al, 2013; Vassiou et al, 2013).
It has been established that there is a high correlation between
metabolites measured by HR-MAS MRS of ex vivo tissue and those
measured using in vivo MRS (Wilson et al, 2009b). Therefore, in
this study, we have assessed the utility of ex vivo HR-MAS MRS to
identify metabolite biomarkers, which define tumour subtypes and
which correlate with histopathology in retinoblastoma. This work
provides the first demonstration that MRS may have significant
value in clinical decision making in retinoblastoma and provides a
foundation for further studies to develop in vivo MRS as a
diagnostic tool for this tumour.
MATERIALS AND METHODS
Clinical samples. Frozen tumour tissue samples from eyes
enucleated without prior treatment were obtained from 52
retinoblastoma patients (48 unilateral, 4 bilateral), treated at
Birmingham Children’s Hospital from 2004 to 2013. Tumours
were selected based on the availability of frozen tissue. Consent was
obtained for tissue banking for ethically approved research. This
study was approved by the local Research Ethics Committee and
the UK Children’s Cancer and Leukaemia Group (CCLG)
Biological Studies Committee.
Histopathology analysis. Following removal of a portion of the
tumour for HR-MAS MRS, the entire enucleated eye was processed
into paraffin as part of standard clinical practice (Sastre et al,
2009), and every 5th–10th section stained with H&E for analysis.
Analysis was carried out independently by two individuals,
including a paediatric pathologist (MAB), across all the slides
from each case (median: 17; range 13–22 slides per case). Criteria
scored included the percentage of rosettes (Flexner–Wintersteiner
(F–W) and/or fleurettes), the percentage of necrosis, level of
apoptosis (localised patches were scored 1, and widespread scatter
was scored 2), and the presence or absence of adverse pathology,
including deep choroid invasion, retrolaminar optic nerve invasion
and scleral invasion. As the presence of F–W rosettes and fleurettes
is considered a marker of differentiation, the percentage of tumour
occupied by rosettes/fleurettes was quantified on a graded scoring
scale as a measure of differentiation. Tumours with o10% of the
tumour occupied by rosettes were scored 1, those with 10–25%
rosettes were scored 2, those with 26–50% rosettes were scored 3,
whereas those with 450% rosettes were scored 4. Necrosis was
defined by the areas of the tumour with cells that were shrunken
and predominantly eosinophilic (stained pink) indicating DNA
breakdown. Apoptotic cells were identified as cells with condensing
and fragmented chromatin (stained blue), often accompanied by
irregular cell size and shape and membrane degradation. Depth of
invasion into the choroid was recorded as deep (43mm)
or superficial (o3mm), and optic nerve invasion was scored as
prelaminar, intralaminar or retrolaminar based on the depth of
intrusion into the optic nerve (Sastre et al, 2009). Histological
analysis was undertaken on the whole paraffin-embedded tumour
rather than on the tissue fragment used for HR-MAS MRS.
However, a small subset of post-HR-MAS MRS tumours (n¼ 10)
were subsequently embedded in paraffin to confirm that the
histological features of the HR-MAS MRS biopsy accurately
reflected those of the whole tumour (Supplementary Table 3).
High-resolution proton magnetic resonance spectroscopy.
High-resolution magic-angle spinning magnetic resonance spec-
troscopy was undertaken at the Henry Wellcome Building for
NMR Spectroscopy at the University of Birmingham. Frozen
tumour tissue was trimmed to fit either a 12 or a 50 ml zirconium
rotor, weighed and 5ml of internal standard (3-trimethylsilylpro-
ponic-2,2,3,3-d4 acid sodium salt (TSP; Cambridge Biosciences,
Cambridge, UK) was added before the rotor was topped up with
deuterium water (Sigma-Aldrich, Dorset, UK). The average tissue
weight of the samples was 21 ±7.8mg (s.d.) and the minimum
size suitable for obtaining good quality spectra was 5mg. All
samples were kept cold over dry ice during preparation to
minimise tissue degradation. High-resolution magic-angle spin-
ning magnetic resonance spectroscopy was carried out using a
Bruker Avance spectrometer (Bruker Biospin, Coventry, UK) at a
field strength of 500MHz with a 4mm three-channel HCD
HR-MRS z-PFG band probe. Samples were spun at 4800Hz at a
BRITISH JOURNAL OF CANCER Metabolite profiling of retinoblastoma
2 www.bjcancer.com |DOI:10.1038/bjc.2015.318
temperature of 4 1C to minimise sample degradation. A pulse-
acquire acquisition was used with 2 s of NOESY presaturation for
water suppression and a repetition time of 4 s. Total acquisition
time was either 17 or 34min depending on sample size.
Data analysis. High-resolution magic-angle spinning magnetic
resonance spectroscopy data analysis of 52 retinoblastomas was
performed using the Mnova NMR 8.2 software suite (2013;
Mestrelab Research, Spain). Data were Fourier transformed,
phased, baseline corrected and chemical shift referencing was
performed relative to the creatine peaks at 3.03 p.p.m. The signal
from spectral regions at 1.14 and 3.67 (representing ethanol
contamination) was removed from all further analysis. Spectra
were then binned into regions of 0.01 p.p.m., normalised to the
total spectral area and the region between 2.6 and 4.0 p.p.m.
subjected to multivariate analyses using principal component
analysis (PCA). The region from 0 to 2.6 p.p.m. was not included
in the multivariate analysis as the lipid and lactate signals dominate
this region and vary greatly across the samples masking
information from the small-molecule metabolites. This is an
approach that has been used in several previous studies (Bathen
et al, 2007). The scores from the principal components were then
plotted. The metabolites that contribute to each PC score were
assessed using the corresponding PC loadings. An unsupervised
hierarchical clustering analysis using a Euclidian distance metric
and average linkage was also undertaken using the same spectral
data. All multivariate statistical methods were carried out using the
Metaboanalyst 3.0 server (2012; The Metabolomics Innovation
Centre, Edmonton, AB, Canada) (Xia et al, 2012).
Quantitation of relevant metabolites identified from loadings
plots produced during multivariate analysis was undertaken in
Mnova NMR for 50 retinoblastomas using the added TSMP as a
concentration reference (Sitter et al, 2010; Moestue et al, 2011).
Two cases from group 3 were excluded from quantification because
of low signal from the TSMP reference peak. Metabolites were
quantified by determining the peak area of the metabolite using a
global spectral deconvolution (GSD) line-fitting algorithm and
comparing to the peak area of the standard at known concentra-
tions. This algorithm facilitates resolution of overlapping and
hidden peaks in crowded areas of the spectrum (Bernstein et al,
2013). The proton number contributing to both the metabolite
signal of interest and TSMP is also taken into account when
performing quantification (Govindaraju et al, 2000). Peaks were
assigned to particular metabolites manually using literature values
and the Human Metabolome Database (Wishart et al, 2013). In
spectral regions with overlapping peaks such as the lipid
resonances, the signal from irrelevant peaks was subtracted from
the GSD analysis before calculating the concentration. Concentra-
tion values were then adjusted according to sample weight and
rotor size. Lipids were quantified as they are known to correlate
with necrosis in tumours. Lipids were assigned according to
Moestue et al (2011), and contributions from macromolecular
resonances were excluded from lipid concentration values.
All statistical comparisons of metabolite concentrations and
histological features between groups were undertaken in SPSS
version 22 (IBM, Armonk, NY, USA) using the nonparametric
Kruskall–Wallis test with significance set at Pp0.05. This was
followed by Mann–Whitney U-test pairwise comparisons as a post
hoc test to identify group-specific differences. Correlations were
examined using Spearman’s rank correlation test or where
appropriate, a point biserial correlation coefficient (rPB).
The Metabolite Pathway Analysis (MetPA) tool of the
Metaboanalyst 3.0 server was used for network analysis of
identified metabolites. MetPA uses pathway enrichment analysis
together with the analysis of pathway topological characteristics to
identify the most relevant metabolic pathways in the system under
study. The pathway impact factor is calculated as the sum of the
importance (centrality) measures of the metabolites of interest,
normalised by the sum of the importance measures of all
metabolites in the pathway (Xia and Wishart, 2010).
RESULTS
HR-MAS MRS of retinoblastoma. High-resolution magic-angle
spinning magnetic resonance spectroscopy of retinoblastoma has not
been reported previously and therefore initial investigation focused on
defining the range of metabolites detectable in these tumours. A total
of 52 retinoblastomas (Supplementary Table 1) were analysed,
revealing readily detectable levels of lactate, valine, alanine, leucine,
glutamate, glutamine, hypotaurine, creatine, choline, phosphocholine,
glycerophosphocholine, phosphoethanolamine, taurine, glycine, lipids,
macromolecules, acetate, GABA, succinate and aspartate (Figure 1).
Principal component analysis of the binned spectral region from
2.6 to 4 p.p.m. indicated that PC1 and PC2 together accounted for
B58% of the variation across the tumours. Based on this analysis,
separation of the tumours into three distinct groups was apparent
(Figures 2A and B). An unsupervised hierarchical clustering
analysis also showed the same classification of tumours into three
separate groups (Figure 2C). Metabolites that map to the spectral
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Figure 1. HR-MRS spectrum typical of retinoblastoma. Lactate (1), valine (2), alanine (3), leucine (4), glutamate (5), glutamine (6), hypotaurine (7),
creatine (8), choline (9), glycerophosphocholine (10), phosphocholine (11), phosphoethanolamine (12), taurine (13), glycine (14), acetate (15), GABA
(16), succinate (17), aspartate (18), lipid (19), ethanol contamination (EtOH).
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bins contributing to this classification include taurine, creatine
(PC1) and choline (PC2) (Figure 2B). Thus, group 1 retinoblas-
tomas are characterised by low taurine and creatine with variable
choline, group 2 by intermediate taurine and creatine but with high
choline and group 3 by increased taurine and creatine, but lower
choline (Figure 2D). Examination of PC3 identified hypotaurine as
a further metabolite of interest, which provided good discrimina-
tion between group 1, where it is very low, and group 2, where it is
particularly high (results not shown). Post-HR-MAS MRS
histopathology review of a subset of 10 retinoblastomas confirmed
that in all cases the tissue was composed entirely of tumour with no
contamination from normal retina.
The primary analysis of spectral binned data maximises the
information available for tumour classification but does not give
precise information on metabolite levels. Therefore, concentrations
of taurine, hypotaurine, choline, creatine and lipids were quantified
and normalised as described in the Materials and Methods section.
Calculation of mean values for each of the three retinoblastoma
groups confirmed that in all cases concentrations of these
metabolites showed significant differences between groups
(detailed in Table 1 and summarised in Table 2).
The most notable differences were observed for taurine
metabolites. Both taurine and hypotaurine were significantly lower
in group 1 compared with groups 2 and 3 (Figure 3). Amounts
were variable in the latter two groups, with significantly higher
hypotaurine in group 2 (2.2-fold increase relative to group 3) and
a trend towards higher taurine in group 3 (1.7-fold increase).
Creatine concentrations showed a similar pattern to taurine (2.4-
and 2.7-fold increases in groups 2 and 3 relative to group 1). An
inverse relationship between lipids and taurine was apparent,
with group 1 retinoblastomas having lipid concentrations 2.1-
and 7.7-fold higher compared with groups 2 and 3, respectively.
Group 2 retinoblastomas were characterised by very high total-
choline concentrations. Measurements of individual choline
metabolites, that is, choline, phosphocholine and glyceropho-
sphocholine, indicated that phosphocholine was largely responsible
for the 3.1-fold increase in total-choline in group 2 relative
to group 1.
Pathway analysis of the quantified metabolites identified the
taurine/hypotaurine metabolic pathway as showing the most
significant difference between the three retinoblastoma subgroups
(impact factor¼ 0.41; FDR-adjusted P-value¼ 0.005). Metabolite
set enrichment analysis of the pathway identified high hypotaurine
and high taurine concentrations as significant features of groups 2
and 3, respectively. The glycerophospholipid pathway was also
significantly different between groups (impact factor¼ 0.08; FDR-
adjusted P-value¼ 0.002), with phosphocholine and glyceropho-
sphocholine contributing most to this difference (Supplementary
Figure 1). This pathway analysis further emphasises the very
distinctive metabolic profiles for each of the retinoblastoma
subgroups and suggests that metabolic pathways involving taurine
and choline metabolites are important in retinoblastoma biology.
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Histopathology of retinoblastoma and its relationship to the
metabolite-based tumour classification. To investigate the clin-
icopathological significance of variations in the retinoblastoma
metabolome, all retinoblastomas were also assessed for histopatho-
logical parameters. These included measures of tumour viability
(necrosis and apoptosis), differentiation (F–W rosettes; Figure 4)
and invasiveness (invasion of the choroid or optic nerve). Each
parameter was assessed across multiple tissue sections from each
retinoblastoma to maximise the accuracy of the analysis.
Independent analysis of the tissue samples used for HR-MAS
MRS was also undertaken for a subset of cases and confirmed that
the HR-MAS MRS tissue was representative of the tumour as a
whole (Supplementary Table 3).
One of the most significant observations from this analysis was
the variation in the level of differentiation among the different
retinoblastoma groups (P¼ 0.015). Most group 1 tumours were
relatively undifferentiated (13 out of 17, 76% with o10% of the
tumour containing F–W rosettes), whereas many group 3 tumours
showed much higher levels of differentiation (35% of tumours with
450% rosettes) (Figure 5 and Supplementary Table 2). The level of
differentiation showed a significant positive correlation with taurine
concentration (P¼ 0.002). Necrosis (but not apoptosis) also varied
significantly between groups (P¼ 0.002) and was higher in the
undifferentiated group 1 tumours (52% necrotic cells) compared
with either group 2 (31%, P¼ 0.0005) or group 3 (35%, P=0.01).
The level of necrosis was positively correlated with total lipids
(P¼ 0.0005) but negatively correlated with taurine (P¼ 0.009),
creatine (P¼ 0.005), hypotaurine (P¼ 0.03), total-choline (P¼ 0.02)
and phosphocholine (P¼ 0.05) (Supplementary Table 2).
Retrolaminar optic nerve invasion was more frequent in group 2
retinoblastomas (6 out of 18, 33%) compared with that in the other
groups (2 out of 17, 12% in both groups 1 and 3). Although this
distribution did not reach statistical significance, it is of interest
that retrolaminar optic nerve invasion was significantly correlated
with higher total-choline (P¼ 0.004) and phosphocholine
(P¼ 0.001) concentrations, which were also a characteristic feature
of group 2 retinoblastomas. No differences were observed in the
frequency of deep choroid invasion between groups.
Table 1. Metabolite concentrations in RB groups
Rb group Metabolites
Taurine Hypotaurine t-Choline Phosphocholine Creatine Total lipid
Group 1 0.22±0.04 0.01±0.006 0.17±0.05 0.13±0.04 0.16±0.04 7.70±1.84
Group 2 0.57±0.11 0.35±0.10 0.52±0.13 0.35±0.09 0.38±0.08 3.74±0.85
Group 3 0.95±0.30 0.16±0.07 0.29±0.07 0.16±0.07 0.43±0.14 1.00±0.35
Kruskall–Wallis P-valuea 0.005 0.0001 0.008 0.007 0.016 0.0003
Post hoc significanceb G1 vs G3 P¼ 0.002 G1 vs G2 P¼ 0.0001 G1 vs G2 P¼0.003 G1 vs G2 P¼0.003 G1 vs G2 P¼0.006 G1 vs G2 P¼ 0.015
G1 vs G2 P¼ 0.006 G1 vs G3 P¼ 0.013 G1 vs G3 P¼0.048 G1 vs G3 P¼ 0.0003
G2vG3 P¼0.03 G2 vs G3 P¼ 0.002
Abbreviations: ANOVA¼ analysis of variance; Rb¼ retinoblastoma.
aNonparametric ANOVA for significance of difference between groups.
bValues p0.05 are considered significant.
Table 2. Relative differences in metabolite concentrations
between retinoblastoma groups
Metabolite Group 1 Group 2 Group 3
Taurine Low Intermed High
Hypotaurine Very low High Intermed
Creatine Low High High
t-Choline Low High Low
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Figure 3. Mean metabolite concentrations in retinoblastoma groups.
(A) Taurine, (B) total-choline, (C) hypotaurine, (D) creatine, (E) individual
choline components and (F) choline containing region of the spectrum:
GPC, glycerophosphocholine (s: singlet, black; t: triplet); PC,
phosphocholine (s, grey); Cho, free choline. (G) Total lipids. *Pp0.05;
between groups statistical significance as determined by Mann–
Whitney U-test post hoc comparisons.
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DISCUSSION
Retinoblastoma differs from most other tumour types in that
diagnosis, staging and treatment decisions must rely on clinical
observations and imaging, without the benefit of input from
histopathology or molecular pathology. This presents a major
problem for the delivery of personalised treatment, particularly as
this is complicated by the need not only to ensure patient survival
but also to attempt globe salvage and preservation of vision. In this
study, we show for the first time that magnetic resonance
spectroscopy potentially is a valuable diagnostic tool in
retinoblastoma. High-resolution magic-angle spinning magnetic
resonance spectroscopy provides a detailed readout of the tumour
metabolome, variations of which are expected to reflect the
upstream genetic mutations, which drive tumour development and
progression. Our results demonstrate that HR-MAS MRS can be
used to discriminate between retinoblastoma subgroups, and in
addition that clinically relevant aspects of tumour biology such as
differentiation and optic nerve invasion are correlated with
metabolic parameters.
The metabolites that contributed most to discrimination between
retinoblastoma groups included taurine, hypotaurine, phosphocholine,
creatine and lipids. Although no single metabolite was exclusively
present in any retinoblastoma group, metabolite concentrations
showed consistent differences between groups, and when considered
in combination, provided group-specific profiles. Group 1 retinoblas-
tomas, for example, were defined by very low taurine, little or no
hypotaurine and low creatine, as well as significantly elevated lipids.
Group 2 retinoblastomas had the highest levels of phosphocholine and
also hypotaurine. Group 3 retinoblastomas were characterised by high
taurine and very low lipid concentrations.
The observation that taurine was highest in group 3 retino-
blastomas and that this group was also the most differentiated, as
determined by the presence of F–W rosettes and fleurettes
(markers of retinal and photoreceptor differentiation; Eagle,
2013) is consistent with reports that taurine has an important
role in retinal and particularly photoreceptor development and
function. Several studies have demonstrated that taurine depletion
is associated with photoreceptor degeneration (Froger et al, 2014).
Conversely, taurine contributes to the in vitro generation of
putative rod and cone photoreceptors from embryonic stem cells
(Osakada et al, 2008). These effects may be mediated at least in
part by neuromodulatory effects of taurine. Taurine is structurally
similar to the neurotransmitters glycine and GABA and has been
shown to activate glycine receptors to stimulate rod photoreceptor
development (Ripps and Shen, 2012). Photoreceptor differentiation
is also influenced by taurine-upregulated gene 1, a non-coding
RNA that modulates the expression of photoreceptor-specific
genes in the retina (Young et al, 2005).
Other cellular functions of taurine include osmoregulation,
calcium modulation and suppression of inflammation, and it also
has antioxidant properties. In addition, it is important in
maintaining the normal respiratory chain function (Schaffer
et al, 2014), a factor that is critical in retinal photoreceptor cells,
as this is one of the most energetically demanding cell types in the
body (Wong-Riley, 2010; Reidel et al, 2011). Consistent with this,
we have shown previously that more differentiated retinoblastomas
express many genes required for photoreceptor function and also
show significant upregulation of pathways associated with
mitochondrial function (Kapatai et al, 2013). The mechanisms
regulating taurine levels in retinoblastoma are unclear but may
involve either regulation of its synthesis from the precursor
hypotaurine and/or regulation of uptake from the extracellular
environment, mediated by the taurine transporter SLC6A6.
Taurine has been implicated as a tumour marker in a number of
different cancer types. The fact that it is both increased (e.g.
colorectal, breast, prostate cancers) and decreased (oesophageal
carcinomas) relative to normal tissue (Swanson et al, 2003; Yang
et al, 2013; Mirnezami et al, 2014) is perhaps not surprising in view
of its multiple functions. However, it is of interest that in breast
cancer, higher taurine levels are associated with improved survival
(Cao et al, 2012; Choi et al, 2012), paralleling the observation of
increase taurine levels in retinoblastomas with a lower frequency of
retrolaminar optic nerve invasion. In the CNS taurine promotes
differentiation along a neuronal, rather than a glial pathway (Ripps
and Shen, 2012), and this is consistent with the detection of
increased levels of taurine in medulloblastomas but not in
astrocytomas or ependymomas (Moreno-Torres et al, 2004;
Davies et al, 2008). Increased taurine levels have also been
reported in neuroblastoma, a tumour of the peripheral nervous
system (Wilson et al, 2009a).
These observations suggest that taurine metabolism in retino-
blastoma is closely linked to aspects of normal retinal/neural
function. In contrast, alteration of total-choline/phosphocholine
metabolism may be regarded as a hallmark of malignant
N
FW
Figure 4. H&E histology of a representative retinoblastoma.
FW, Flexnor–Wintersteiner rosettes characteristic of differentiated
retinoblastoma (the arrows point to individual examples of well-defined
rosettes). N, necrotic tumour (stained pink).
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Figure 5. Histopathology of retinoblastoma metabolic groups.
(A) Differentiation, (B) necrosis, (C) retrolaminar optic nerve invasion
and (D) deep choroid invasion.
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transformation and is a much more general characteristic of many
different tumour types (Righi et al, 2009; Glunde et al, 2011; Ward
et al, 2013). Phosphocholine is both a precursor and a breakdown
product of cellular membranes and its metabolism is important for
cellular proliferation. Total-choline and phosphocholine are also
increased in response to hypoxia (Glunde et al, 2011). There is
evidence to suggest that choline metabolism is regulated by
oncogenic signalling, involving, for example, RAS and PI3K/AKT,
as well as transcription factors including JUN, MYC, MYCN and
HIF1, which regulate enzymes and transporters in the choline
pathway (Ronen et al, 2001; Peet et al, 2007; Glunde et al, 2011).
Increased total-choline levels have been associated with aggres-
siveness in breast, prostate and brain tumours (Peet et al, 2007;
Righi et al, 2009; Glunde et al, 2011). This is consistent with our
findings in retinoblastoma that increased total-choline and
phosphocholine were significantly correlated with retrolaminar
optic nerve invasion (Pp0.004). The total-choline : creatine ratio
has also been used as a measure of malignancy and combines
measures of proliferative capacity (total-choline) with energy
metabolism (tumours with high metabolic activity tend to have
depleted energy stores and low creatine) (Martinez-Bisbal and
Celda, 2009). Using this ratio, retinoblastomas may be classified in
increasing order of malignancy: group 3 (total-choline : creatine
ratio: 0.6)ogroup 1 (1.1)ogroup 2 (1.4).
Group 1 retinoblastomas showed the highest levels of lipids.
Only mobile lipids (not membrane-associated lipids) are visible in
MR spectra, and consequently these are likely to originate from
cytoplasmic lipid droplets. The presence of lipid droplets has been
correlated with necrosis and/or apoptosis (Abramson, 2005), and
this is consistent with the observation of increased necrosis in this
retinoblastoma group. However, these retinoblastomas frequently
also contained abundant mitoses (results not shown), and
increased necrosis may be a response to hypoxic conditions, as
might be found where there is extensive tumour growth within the
vitreous. Therefore, these retinoblastomas may have reduced
capacity to maintain growth when the nutrient supply is limiting.
Our results suggest that metabolomic investigation of retino-
blastoma has the potential to provide clinically useful information
about tumour characteristics. It is important, however, to consider
the challenges involved in replicating this work using noninvasive
in vivo MRS in patients. In vivo MRS has lower resolution
compared with HR-MAS MRS; nevertheless, the key metabolites
of interest that we have identified ex vivo have already been
quantified in in vivo MRS studies. In paediatric brain tumours, for
example, significant changes in mean metabolite concentrations in
the range of 1.3- to 5-fold for taurine, lipid, creatine and choline
accurately discriminate between tumour types (Davies et al, 2008).
It is likely, therefore, that differences of this magnitude in taurine,
choline and lipids could also be detected in vivo in retinoblastoma.
Previous work from our group has shown that successful and
accurate in vivo quantification can be performed with software
such as LC model and Tarquin (Reynolds et al, 2006; Davies et al,
2008) and that these values correlate well with ex vivo metabolite
concentrations from the same samples (Wilson et al, 2009b).
Continuing technical developments in the MRI field will also
contribute to improved MRS. The use of small surface coils, for
example, is of great value where there is a requirement for high
spatial resolution in a small field of view. These have already been
used succesfully to investigate extrascleral extension in uveal
melanoma (Tartaglione et al, 2014) and have also been shown to be
of value for the detection of postlaminar optic nerve invasion and
choroidal invasion in children with retinoblastoma (Sirin et al,
2015). The development of scanners that operate at higher
magnetic field strengths will also increase the sensitivity of
MRI/MRS. Currently, clinical scanners operate at 1.5 or 3.0 Tesla,
but studies on enculeated eyes using ultrahigh-field (7 Tesla)
magnetic resonance microscopy have demonstrated the potential
for the differential diagnosis of intraocular masses (Falke et al,
2013), and the feasibility of 7 T MRI in vivo has also been
demonstrated (Richdale et al, 2009; Graessl et al, 2014).
In conclusion, the results of this study confirm previous genetic
investigations showing heterogeneity among retinoblastomas, with
loss of differentiation associated with a more invasive phenotype
(Kapatai et al, 2013). Our metabolomic studies provide additional
information about the biological differences between these
retinoblastoma groups and suggest that even within less differ-
entiated tumours, different metabolite profiles may allow further
stratification, for example, retinoblastomas with increased lipids
may be more necrotic and have less potential for progressive
growth compared with retinoblastomas that have lower lipids, high
phosphocholine and a high total-choline : creatine ratio.
The potential to stratify retinoblastomas noninvasively, using
magnetic resonance spectroscopy, is of immense clinical signifi-
cance in view of the increasing use of intra-arterial chemotherapy.
Intra-arterial chemotherapy can produce marked tumour shrink-
age, and the possibility for preservation of vision is also a very
major consideration for patients (Shields et al, 2014). However,
IAC does not treat systemic micrometastatic disease and thus very
careful selection of patients is required to minimise the risk of
potentially fatal extraocular metastasis. The findings reported here
will require further validation to ascertain the full clinical relevance
of these retinoblastoma subgroups; nevertheless, the results of this
study indicate that metabolomic investigation using magnetic
resonance spectroscopy could make a significant contribution to
risk assessment in retinoblastoma patients, if as shown successfully
in other studies, in vivo results correlate well with ex vivo
data(Martinez-Bisbal and Celda, 2009; Wilson et al, 2009b). Future
research must focus therefore on further validation of our findings
and replicating our ex vivo data using in vivo magnetic resonance
spectroscopy in a clinical setting, as well as determining the
underlying genetic and biological basis of the metabolomic
subgroups.
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